Application of ⁸⁹Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

ABSTRACT:

Purpose

The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer's disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques for brain imaging of antibodies may guide decision-making in the future but needs further development. In this study, we used ⁸⁹Zr-immuno-PET to evaluate the targeting and distribution of a bispecific brain-shuttle IgG based on Adu with transferrin receptor protein-1 (TfR1) shuttling mechanism, mAbAdu-scFab8D3, designated Adu-8D3, as a candidate theranostic for AD. We also validated the ⁸⁹Zr-immuno-PET platform as an enabling technology for developing new antibody-based theranostics for brain disorders.

Methods

SUBMITTER: Stergiou N 

PROVIDER: S-EPMC10027647 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature